ECZTEND: Tralokinumab-ldrm Achieves Lasting Efficacy in AD Patients
Key Takeaways:
- Six-year data on tralokinumab-ldrm show no new safety concerns for moderate-to-severe AD patients.
- 92.9% of patients reached EASI-75, and 66.7% achieved clear or nearly clear skin scores (IGA 0/1).
- Patients experienced reductions in itch and better sleep, resulting in an improvement in life quality.
Final results presented at Fall Clinical 2024 from the ECZTEND study confirmed long-term safety and efficacy of tralokinumab-ldrm in adolescents and adults with moderate-to-severe atopic dermatitis (AD).
The open-label, single-arm trial included 1,672 participants who transitioned from nine parent trials to receive up to five additional years of treatment in ECZTEND. Long-term safety was consistent with initial findings from the placebo-controlled parent trials, according to a news release from the manufacturer. According to the efficacy data, 92.9% of patients achieved a 75% reduction in Eczema Area and Severity Index (EASI-75) at Week 248, and 66.7% of patients reached an Investigator's Global Assessment score of 0 (clear) or 1 (almost clear).
"These long-term findings are crucial for clinical practice, providing healthcare professionals with the data needed to prescribe tralokinumab-ldrm for sustained use confidently," said Dr. Andrew Blauvelt, the study’s International Coordinating Investigator, in a press release.
Alongside improvements in physical symptoms, patients also reported improved quality of life, including better sleep and itch relief. Adverse events were generally mild or moderate, with fewer reported cases in ECZTEND compared to initial trials.
"With the release of the final results from the ECZTEND open-label extension study, we are pleased to present robust evidence further supporting the long-term safety and efficacy of tralokinumab-ldrm in the treatment of moderate-to-severe atopic dermatitis," said Brian Hilberdink, EVP and President, Region North America, LEO Pharma, in a press release. "This important milestone underscores our unwavering commitment to transforming the lives of the millions of Americans affected by this chronic condition. With this new evidence and a single-dose autoinjector now available for adults in the U.S., we are excited to empower patients to help manage their symptoms for the long term."